scholarly article | Q13442814 |
P819 | ADS bibcode | 2012PLoSO...748524P |
P356 | DOI | 10.1371/JOURNAL.PONE.0048524 |
P932 | PMC publication ID | 3485360 |
P698 | PubMed publication ID | 23119046 |
P5875 | ResearchGate publication ID | 232766830 |
P50 | author | Beatriz Perdiguero | Q112248161 |
Jose Luis Nájera | Q114406498 | ||
Rubén González-Sanz | Q114406499 | ||
Mariano Esteban | Q30004051 | ||
Carlos Oscar Sanchez Sorzano | Q56027899 | ||
Thierry Calandra | Q56616768 | ||
Giuseppe Pantaleo | Q88061163 | ||
Thierry Roger | Q40228404 | ||
Carmen E Gómez | Q42100464 | ||
P2093 | author name string | Julie Delaloye | |
Victoria Jiménez | |||
P2860 | cites work | A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses | Q21135240 |
Viruses and Apoptosis | Q22255620 | ||
Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis | Q24302248 | ||
The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax | Q24310440 | ||
Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands | Q24321449 | ||
Susceptibility of different leukocyte cell types to Vaccinia virus infection | Q24801903 | ||
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions | Q27320923 | ||
Dendritic cells and the control of immunity | Q27860918 | ||
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis | Q28292299 | ||
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome | Q28389050 | ||
Viral control of mitochondrial apoptosis | Q28472776 | ||
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors | Q28742751 | ||
Improved NYVAC-based vaccine vectors | Q28742982 | ||
The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 | ||
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
The biochemistry of apoptosis | Q29547741 | ||
Molecular mechanisms of caspase regulation during apoptosis | Q29617861 | ||
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine | Q30977303 | ||
Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). | Q33320536 | ||
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo | Q33328336 | ||
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens | Q33627613 | ||
Vaccinia virus protein F1L is a caspase-9 inhibitor | Q33648434 | ||
Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis | Q33717065 | ||
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate | Q33749950 | ||
Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor | Q33912043 | ||
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals | Q33916776 | ||
Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa. | Q33941041 | ||
Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes | Q33962664 | ||
Cross-presentation in viral immunity and self-tolerance. | Q34119651 | ||
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein | Q34182371 | ||
Immunology 102 at poxvirus U: avoiding apoptosis. | Q34209976 | ||
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. | Q34247289 | ||
Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells | Q34332462 | ||
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses | Q34469355 | ||
Induction of immunity to human immunodeficiency virus type-1 by vaccination | Q34540645 | ||
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles | Q34772727 | ||
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine | Q35009558 | ||
Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. | Q35024193 | ||
Structural determinants of caspase-9 inhibition by the vaccinia virus protein, F1L | Q35182960 | ||
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery | Q35551800 | ||
Ways of dying: multiple pathways to apoptosis. | Q35560936 | ||
Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice | Q35943846 | ||
Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells | Q45734461 | ||
Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells | Q45736403 | ||
Quantification of antigen specific CD8+ T cells using an ELISPOT assay | Q47999428 | ||
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. | Q51968415 | ||
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load | Q57259602 | ||
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C | Q79561534 | ||
Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses | Q80445239 | ||
Lead and follow: the dance of the dendritic cell and T cell | Q81020106 | ||
Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. | Q36315031 | ||
Near death experiences: poxvirus regulation of apoptotic death | Q36346832 | ||
Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation | Q36376037 | ||
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara | Q36692389 | ||
Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection | Q37248017 | ||
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge | Q37287080 | ||
Nonreplicating vaccinia vector efficiently expresses recombinant genes | Q37299518 | ||
Viral inhibitors reveal overlapping themes in regulation of cell death and innate immunity | Q37592685 | ||
Poxvirus vector-based HIV vaccines | Q37803318 | ||
MVA and NYVAC as vaccines against emergent infectious diseases and cancer. | Q37859845 | ||
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). | Q38484762 | ||
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. | Q38725610 | ||
The vaccinia virus-encoded Bcl-2 homologues do not act as direct Bax inhibitors | Q39455647 | ||
Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1. | Q39539847 | ||
Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine | Q39589039 | ||
The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation | Q39611834 | ||
Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model | Q39790409 | ||
Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression | Q39897867 | ||
The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection | Q40390611 | ||
Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara | Q40506182 | ||
Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors | Q40542008 | ||
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox | Q40579847 | ||
Vaccinia virus F1L protein is a tail-anchored protein that functions at the mitochondria to inhibit apoptosis | Q40722650 | ||
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs | Q41057373 | ||
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line | Q41076591 | ||
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence | Q41684943 | ||
Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates | Q42100401 | ||
Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. | Q42702068 | ||
Isolation of mouse peritoneal cavity cells | Q42858996 | ||
Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellu | Q43456447 | ||
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers | Q44590524 | ||
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. | Q45235855 | ||
Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells. | Q45369720 | ||
The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity | Q45411290 | ||
Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity | Q45418101 | ||
The vaccinia virus N1L protein influences cytokine secretion in vitro after infection | Q45421140 | ||
Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. | Q45421530 | ||
Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis | Q45437312 | ||
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans | Q45723463 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | apoptotic process | Q14599311 |
HIV/AIDS | Q12199 | ||
P304 | page(s) | e48524 | |
P577 | publication date | 2012-10-31 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens | |
P478 | volume | 7 |
Q37209483 | Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants |
Q47552501 | Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity |
Q38156198 | Clinical applications of attenuated MVA poxvirus strain. |
Q36947039 | Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses. |
Q92716321 | Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy |
Q35656345 | Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity |
Q89633807 | Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B |
Q37643731 | Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. |
Q27306437 | Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C |
Q27321985 | Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection |
Q33602820 | Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses |
Q47233214 | E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox |
Q36978452 | Enhancing poxvirus vectors vaccine immunogenicity. |
Q40339467 | HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci |
Q45325213 | Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? |
Q40843765 | Illuminating inflammasome activity in vivo. |
Q47252143 | Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways |
Q40071705 | Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models |
Q34796206 | Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways |
Q50533334 | Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory. |
Q90434144 | Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses |
Q36980878 | Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. |
Q36192765 | Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012) |
Q33870595 | Structure of vaccinia virus A46, an inhibitor of TLR4 signaling pathway, shows the conformation of VIPER motif |
Q56556724 | The Gene of Goatpox Virus Encodes an Inhibitor of NF-κB and Apoptosis and May Serve as an Improved Insertion Site To Generate Vectored Live Vaccine |
Q26995905 | The evolution of poxvirus vaccines |
Q103027729 | Viral Bcl2s' transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis |
Q34991112 | Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. |
Search more.